Stockscreener 앱 받기
4.37
2.82%
0.12
시간 외 거래:
4.37
전일 마감가:
$4.25
열려 있는:
$4.2
하루 거래량:
1.77M
Relative Volume:
0.87
시가총액:
$840.46M
수익:
$14.61M
순이익/손실:
$-42.28M
주가수익비율:
-19.69
EPS:
-0.2219
순현금흐름:
$-44.78M
1주 성능:
+1.16%
1개월 성능:
+3.07%
6개월 성능:
+2.82%
1년 성능:
+32.02%
1일 변동 폭
$4.14
$4.39
1주일 범위
$4.14
$4.45
52주 변동 폭
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
명칭
Arbutus Biopharma Corp
전화
604-419-3200
주소
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.37 | 817.38M | 14.61M | -42.28M | -44.78M | -0.2219 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-02-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 개시 | Jefferies | Hold |
| 2020-12-17 | 개시 | H.C. Wainwright | Buy |
| 2020-07-27 | 재개 | JMP Securities | Mkt Outperform |
| 2020-07-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-06 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 개시 | Robert W. Baird | Outperform |
| 2020-02-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 재확인 | B. Riley FBR | Buy |
| 2019-10-04 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2018-10-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-06 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 재개 | Chardan Capital Markets | Buy |
| 2018-03-19 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 재확인 | Wedbush | Outperform |
| 2016-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
모두보기
Arbutus Biopharma Corp 주식(ABUS)의 최신 뉴스
Arbutus Biopharma Hits Day Low of $4.21 Amid Price Pressure - Markets Mojo
Foursixthree Capital LP Has $8.99 Million Stake in Arbutus Biopharma Corporation $ABUS - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 8.4%Time to Sell? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Moderna Settles Patent Litigation with Arbutus et al. - JD Supra
Arbutus Biopharma Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com
Moderna to Pay About $1 Billion to Settle Arbutus Litigation - Claims Journal
Here's Arbutus Biopharma's share of $950M Moderna settlement - The Business Journals
Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Arbutus Biopharma (ABUS) Reaches Settlement with Moderna Over Pa - GuruFocus
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal By Investing.com - Investing.com Canada
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - Finviz
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com
ABUS: Key Developments and Market Impact - GuruFocus
Moderna's $950 Million Settlement Clears Legal Overhang, Stock SoarsModerna (NASDAQ:MRNA) - Benzinga
Moderna to pay about US$1 bil to settle Arbutus litigation - The Edge Malaysia
Genevant and Arbutus agree $2.25 billion global settlement with Moderna - The Pharma Letter
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Moderna Settles for $950 Million with Arbutus, Eyes Future Growth - Intellectia AI
Moderna Shares Rise 16% After Company Enters Settlement Agreement With Arbutus Biopharma, Genevant Sciences - Bitget
Moderna To Pay At Least $950M To End COVID-19 Vax IP Fight - Law360
Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement - PharmaLive
Moderna agrees to pay nearly $1B to settle Covid vaccine patent battle - The Business Journals
Arbutus Biopharma (ABUS) and Genevant Reach $2.25 Billion Settle - GuruFocus
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna - TipRanks
Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement - Investing.com
Roivant's Genevant and Arbutus reach $2.25 billion settlement with Moderna - StreetInsider
Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement - Stock Titan
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewswire
$2.25 billion Moderna deal ends COVID vaccine patent fight - Stock Titan
Moderna Royalty Loss Raises Covid-Shot Trial Stakes (Correct) - Bloomberg Law News
Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury - TradingView
Key patent ruling boosts Arbutus Biopharma (NASDAQ: ABUS) in Moderna LNP case - Stock Titan
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Intellectia AI
Delaware Court Narrows Moderna’s Invalidity Defenses Ahead of Arbutus LNP Patent Trial - IPWatchdog.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Two Seas Capital reports 6.5% Arbutus Biopharma (ABUS) ownership - Stock Titan
What insider trading reveals about Arbutus Biopharma Corporation stockMarket Risk Summary & Fast Entry and Exit Trade Plans - mfd.ru
Will Arbutus Biopharma Corporation stock remain a Wall Street favorite2025 Top Decliners & Comprehensive Market Scan Insights - mfd.ru
Moving Averages: How does Arbutus Biopharma Corporation correlate with NasdaqWeekly Investment Report & Smart Investment Allocation Insights - baoquankhu1.vn
Court narrows but sustains Arbutus (NASDAQ: ABUS) patent claims in Moderna COVID-19 vaccine fight - Stock Titan
PATENT—D. Del.: Most COVID-19... - VitalLaw.com
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.8%What's Next? - MarketBeat
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal B - GuruFocus
Arbutus Biopharma (ABUS) Rises on Patent Dispute Jury Trial Deci - GuruFocus
Arbutus Biopharma (ABUS) Shares Surge Amid Market Fluctuations - GuruFocus
Arbutus Biopharma (ABUS) Patent Dispute Over COVID-19 Vaccine De - GuruFocus
Arbutus jumps on ruling in patent dispute with Moderna (ABUS:NASDAQ) - Seeking Alpha
Arbutus Biopharma Corp (ABUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):